-

HCA Healthcare, Inc. to Present at September Healthcare Conference

NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) is scheduled to present at the following healthcare conference:

September 13, 2022 at 8:35 am EDT at the Morgan Stanley 20th Annual Global Healthcare Conference held at the Sheraton New York in New York, NY.

A link to the live audio webcast, where applicable, and copies of any related presentation materials will be made available at the Investor Relations section of the Company’s website, www.hcahealthcare.com.

Dates and times may be subject to change, please check the conference schedule or the Investor Relations section of the Company’s website for the latest information.

All references to “Company” and “HCA” as used throughout this release refer to HCA Healthcare, Inc. and its affiliates.

Contacts

INVESTOR CONTACT:
Frank Morgan
615-344-2688

MEDIA CONTACT:
Harlow Sumerford
615-344-1851

HCA Healthcare

NYSE:HCA

Release Versions

Contacts

INVESTOR CONTACT:
Frank Morgan
615-344-2688

MEDIA CONTACT:
Harlow Sumerford
615-344-1851

More News From HCA Healthcare

HCA Healthcare, Inc. 2nd Quarter 2026 Earnings Conference Call

NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) announces the following Webcast: What: HCA Healthcare, Inc. 2Q 2026 Earnings Call When: Friday, July 24, 2026, at 9:00 AM Central (10:00 AM Eastern) How: Live Audio over the Internet: https://investor.hcahealthcare.com/events-and-presentations/default.aspx Contact: Frank Morgan, 615-344-2688, Vice President, Investor Relations, frank.morgan@hcahealthcare.com If you are unable to listen during the live webcast, the call will be...

HCA Healthcare Previews Second Quarter 2026 Results

NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) today announced preliminary financial and operating results for the second quarter ended June 30, 2026. The preliminary financial and operating results are subject to finalization of the Company's quarterly financial and accounting procedures. HCA anticipates revenues in the second quarter of 2026 to approximate $20.230 billion, compared to $18.605 billion in the second quarter of 2025. Net income attributable to HCA Healthcare...

HCA Healthcare Announces New England Journal of Medicine Study Highlighting Advances in CRISPR-based Therapy for Children

NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE:HCA), one of the nation's leading healthcare providers, today announced new research published in The New England Journal of Medicine (NEJM) demonstrating promising results from a gene-editing therapy being investigated in children ages 5-11 with severe sickle cell disease and transfusion-dependent beta thalassemia. Sickle cell disease and beta thalassemia are inherited blood disorders that can cause serious, lifelong complications b...
Back to Newsroom